A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
for Non Small Cell Lung Cancer (Squamous or Non Squamous)
9 locations incl. Daphne
Sponsor: Eikon Therapeutics
Sex: All·Age: 18+
Code: NCT07365319·Phase 2, Phase 3·Recruiting·Listed Jan 2026